RT Journal Article
SR Electronic
T1 Effects of a single-dose methylphenidate challenge on resting-state functional connectivity in stimulant-treatment naive children and adults with ADHD
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.04.22270336
DO 10.1101/2022.02.04.22270336
A1 Antonia Kaiser
A1 Caroline Broeder
A1 Jessica Cohen
A1 Linda Douw
A1 Liesbeth Reneman
A1 Anouk Schrantee
YR 2022
UL http://medrxiv.org/content/early/2022/02/08/2022.02.04.22270336.abstract
AB Prior studies suggest that methylphenidate, the primary pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), alters functional brain connectivity. As the neurotransmitter systems targeted by methylphenidate undergo significant alterations throughout development, the effects of methylphenidate on functional connectivity may also be modulated by age. Therefore, we assessed the effects of a single methylphenidate challenge on brain network connectivity in stimulant-treatment naïve children and adults with ADHD. We obtained resting-state functional MRI from 50 boys (10-12 years of age) and 49 men (23-40 years of age) with ADHD (DSM IV, all subtypes), before and after an oral challenge with 0.5 mg/kg methylphenidate; and from 11 boys and 12 men as typically-developing controls. Connectivity strength (CS), eigenvector centrality (EC), and betweenness centrality (BC) were calculated for the striatum, thalamus, dorsal anterior cingulate cortex (dACC), and prefrontal cortex (PFC). In line with our hypotheses, we found that methylphenidate decreased measures of connectivity and centrality in the striatum and thalamus in children with ADHD, but increased the same metrics in adults with ADHD. Surprisingly, we found no major effects of methylphenidate in the dACC and PFC in either children or adults. Interestingly, pre-methylphenidate, participants with ADHD showed aberrant connectivity and centrality compared to controls predominantly in frontal regions. Our findings demonstrate that methylphenidate’s effects on connectivity of subcortical regions are age-dependent in stimulant-treatment naïve ADHD patients, likely due to ongoing maturation of dopamine and noradrenaline systems. These findings highlight the importance for future studies to take a developmental perspective when studying the effects of methylphenidate treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by a personal research grant awarded to LR by the Academic Medical Center, University of Amsterdam, and 11.32050.26 ERA-NET PRIOMEDCHILD FP 6 (EU) and a grant from Amsterdam Brain and Cognition (ABC). AK was supported by Suffugium, a Dutch non-profit organization, and Amsterdam Neuroscience. AK and LR were financially supported by EUROSTARS (E!113351 DEPREDICT). AS is supported by the NWO (Veni: 016.196.153) and the Urban Mental Health program of the University of Amsterdam. The authors have nothing to disclose.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the medical ethical committee and consequently monitored by the Clinical Research Unit of the Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors